Sign In
Last checked at 
31 Jul 2013 15:41
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters
1. | Name of the Issuer:
Hikma Pharmaceuticals PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006): DTR 3.1.2 R |
3. | Name of person discharging managerial responsibilities/director: Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry | 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person: Yes: Darhold Limited |
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest: Beneficial interest Darhold Limited | 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares: Ordinary Shares |
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them: Bank Sarasin & Co Ltd (known as Bank J. Safra Sarasin Ltd from 13 June 2013) | 8. | State the nature of the transaction: Grant of a pledge over 2,000,000 Ordinary Shares in support of a loan |
9. | Number of shares, debentures or financial instruments relating to shares acquired: None | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage): N/A |
11. | Number of shares, debentures or financial instruments relating to shares disposed: None | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage): N/A |
13. | Price per share or value of transaction: N/A | 14. | Date and place of transaction: London, July 30, 2013
|
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage): 57,183,028 - 28.88 per cent. | 16. | Date issuer informed of transaction: July 30, 2013 |
If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes | |||
17. | Date of grant | 18. | Period during which or date on which exercisable |
19. | Total amount paid (if any) for grant of the option | 20. | Description of shares or debentures involved (class and number) |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise | 22. | Total number of shares or debentures over which options held following notification |
23. | Any additional information | 24. | Name of contact and telephone number for queries |
Name of authorised official or issuer responsible for making notification |
Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC |
Date of notification: July 31, 2013 |
Notes:
This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4
(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
Follow the stocks
